Document is current
Any future updates will be listed below
-
Authors
Vambe, Debrah
Kay, Alexander
Ziyane, Mangaliso
Thunzini, Mdigo
Thi, Sein Sein
de Araujo, Leonardo
Dreyer, Viola https://orcid.org/0000-0003-2997-3693
Niemann, Tanja
Sibandze, Busizwe
Masina, Sijabu
Cabibbe, Andrea Maurizio https://orcid.org/0000-0001-9727-6465
Furin, Jennifer
Mazuruse, Tafadzwa https://orcid.org/0000-0002-8800-8976
Dlamini, Lindokuhle
Jele, Thulani
Mamba, Bheki
Maphalala, Gugu
Dlamini, Makhosazana
Dube, Mbongeni
Lukhele, Nomthandazo
Cirillo, Daniela Maria https://orcid.org/0000-0001-6415-1535
Mandalakas, Anna https://orcid.org/0000-0002-8091-3509
Lange, Christoph https://orcid.org/0000-0002-9691-4741
Ngwenya, Sphiwe
Utpatel, Christian
Dlamini, Sindisiwe
Niemann, Stefan https://orcid.org/0000-0002-6604-0684
- License Information
-
More Information
Article History
Received: 13 September 2024
Accepted: 13 May 2026
First Online: 11 June 2026
Competing interests
: A.M.M. has received honoraria from JANSSEN for participation in a data and safety monitoring board outside the scope of this work. C.L. has received speakers´ honoraria from Astra Zeneca, GSK, Gilead, Insmed, Jansen, MedUpdate and MedUpdateEurope and served on the WHO advisory board for target product profiles for novel TB regimens and on the WHO guideline development committee for the drug-resistant TB and is a scientific advisor for MSF for drug-resistant TB drug trials. All the other authors declare no competing interests.
